OPHLF - Ono Pharmaceutical Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD

Ono Pharmaceutical Co., Ltd.

8-2, Kyutaromachi 1-chome
Osaka 541-8564
81 6 6263 5670

IndustryDrug Manufacturers—General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Gyo SagaraCEO, Pres & Representative DirectorN/AN/A1958
Mr. Shozo Matsuoka Ph.D.Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QAN/AN/AN/A
Yukio TaniCorp. Exec. Officer & Head of Corp. CommunicationsN/AN/AN/A
Katsuji TeranishiCorp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.N/AN/AN/A
Mr. Isao OnoExec. Officer, Director of Corp. Research & DirectorN/AN/A1959
Mr. Hiroshi IchikawaCorp. Officer & Sr. Director of Medical External AffairsN/AN/AN/A
Mr. Toichi Takino Ph.D.Sr. Exec. Officer, Exec. Director of Discovery & Research and DirectorN/AN/A1968
Mr. Toshihiro TsujinakaSr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and DirectorN/AN/A1964
Hiromu Habashita Ph.D.Corp. Officer and Deputy Exec. Director of Discovery & Research DivisionN/AN/AN/A
Kiyoaki IdemitsuExec. Officer, Exec. Director of Clinical Devel. & DirectorN/AN/A1964
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Corporate governance

Ono Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 June 2023 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.